Announcement PDF RNS Number : 9194F N4 Pharma PLC 24 March 2022 24 March 2022 N4 Pharma Plc ("N4 Pharma" or the "Company") Result of Annual General Meeting N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce that at its annual general meeting ("AGM"), held earlier today, all resolutions were duly passed. The results of the proxy voting for the AGM are set out below. Resolution (*Special Resolution) Total Shares Voted 1. To receive the annual report and audited accounts for the year ended 31 December 2021 2. To re-elect Nigel Theobald as a Director of the Company 3. To re-elect David Templeton as a Director of the Company Shares % For Against For Against 20,171,351 20,171,151 200 99.999 0.001 20,195,551 20,026,641 168,910 99.164 0.836 20,195,551 20,016,641 178,910 99.114 0.886 Resolution (*Special Resolution) Total Shares Voted 4. To reappoint Saffery Champness LLP as auditor to the company and authorise the directors to determine their remuneration 5. To authorise the Directors to allot shares 6*. To disapply pre-emption rights Shares % For Against For Against 20,193,244 19,930,222 263,022 98.697 1.303 20,192,844 19,694,856 497,988 97.534 2.466 20,190,444 19,928,374 262,070 98.702 1.298 Enquiries: N4 Pharma Plc Nigel Theobald, CEO Luke Cairns, Executive Director Via IFC Advisory SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Caroline Rowe (Corporate Finance) Vadim Alexandre/Rob Rees (Corporate Broking) Tel: +44 (0)20 3470 0470 Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker Tel: +44 (0)20 3657 0050 IFC Advisory Limited Financial PR Graham Herring Zach Cohen Tel: +44 (0)20 3934 6630 About N4 Pharma N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®. N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END RAGBBGDXCDDDGDS